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A B S T R A C T
A brief history of human genetics: Sixty years is an appropriate yardstick for many reasons, not least for the
remarkable advances in medicine, public health, psychology and biological disciplines. Particularly
relevant is the approaching 60th anniversary of the discovery of the structure of DNA, which unlocked
the driving force of nature and spawned a plethora of scientiﬁc discoveries and economic development
through the Bitoech industry. Prior to 1953, and before Watson and Crick burst into the Cambridge pub
with their eureka moment, it was known that chromosomes were important, the ﬁrst principles of
clinical cytogenetics were emerging and the rules of heritable traits werewell-advanced, butwithout the
basic framework or mechanism. Human Molecular Genetics arrived when the ﬁrst mutations were
linked to human disorders reﬂecting the advances in understanding the genetic code, assembly of
protein building blocks and methodological advances in reading the physical code (all be it very difﬁcult
process at the time). Accelerated by the introduction of recombinant gene technology in the 1980s, and
in conjunction with the development of linked genetic marker maps, the catalogue of genes associated
with disease has risen exponentially with classical examples such as sickle cell disease, cystic ﬁbrosis
and Huntington’s disease. The advances approached super-sonic dimensions when genes were found in
Mendelian families, andmapping strategies were adopted using the variationmap of the human genome
(SNP’s, di-nucleotide repeats), in addition to targeted candidate gene approaches aided by the signiﬁcant
database resources available to investigators. Super-sonic gave way to light-speed with the publication
of the 3 billion letters of the genetic code which constitutes the human genome, followed quickly by
genomes in plants, bacteria, pathogens, fruits and vegetables, and a menagerie of eukaryotic and
prokaryotic animals, often representing model systems for genomic and pathophysiological research. In
short don’t blink or you’ll miss the next revolution – too late, it’s just happened!
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The past 15 years has witnessed a golden age of gene-discovery
in idiopathic and syndromic epilepsy. Unlike other complex
neurological or psychiatric conditions, idiopathic epilepsy enjoys
the privilege of informative Mendelian autosomal dominant (AD)
families that provide a direct insight into the neurobiology of the
condition. The compendium has grown to around 21 genes in
idiopathic generalised epilepsy (IGE), the vast majority of which
are channelopathies or regulate the action of excitatory or
inhibitory neurotransmission in the central nervous system
(CNS) (Table 1). Other genetic insights have been gained through
the discoveries in syndromic epilepsy and in conditions where
epilepsy is co-morbidwith other disorders such as broad-spectrum
encapthalopathies, learning difﬁculties, psychiatric conditions and* Correspondence address: Institute of Life Science, School of Medicine, Swansea
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doi:10.1016/j.seizure.2010.10.029cortical migration disorders. Despite this success, one of the
limitations of these discoveries is the lack of impact from a wider
population-wide perspective, with the notable exception of SCN1A
and Dravet syndrome and LgI1 in well-deﬁned temporal lobe
epilepsy with auditory features. The ascertainment of the
dominant or X-linked families has created a bias of discovery in
favour of receptor subunits, because they exert their effects
courtesy of compromised multi-meric ion channels that are
particularly susceptible to dominant modulation of channel
function. Despite this extraordinary period of gene-discovery
and neurobiological mechanisms of epileptogenesis, it remains
that the majority of epilepsy patients have no genetic explanation
and this represents one of the many challenges for future epilepsy
research.
2. Dr. Mendel and familial epilepsy
The principles of Mendelian inheritance have been the driving
force for epilepsy gene-discovery. Since 1995 there has been a
steady stream of genes identiﬁed in familial idiopathic epilepsy1–4
and was made possible by pedigrees that typically follows avier Ltd. All rights reserved.
Table 1
Genes associated with familial idiopathic epilepsy.
Gene symbol Epilepsy phenotype OMIM Chromosome
Na channel
SCN1A GEFS+, SMEI 607208 2q24
SCN1B GEFS+ 604233 19q13.1
SCN2A BFNIS 604233 2q23
Ca channel
CACNA1A IGE, EA, SCA6, FHM 600669, 108500 19p13
CACNB4 IGE, JME 600669, 606904 2q22–23
CACNA1H CAE 607682 16p13.3
Ach receptor
CHRNA4 ADNFLE1 600513 20q13.2–q13.3
CHRNB2 ADNFLE3 605375 1p21
GABAA receptors
GABRA1 JME 606904 5q34
GABRG2 GEFS+, CAE 604233, 607681 5q34
GABRD GEFS+ 604233 1p36.3
Cl channel
CLCN2 CAE, EGMA 607682, 607628 3q26
K channel
KCNQ2 BFNC1 105370 20q13.3
KCNQ3 BFNC2 121201 8q24
LGI1 ADPEAF 600512 10q24
The various channelopathies associated with idiopathic epilepsy affecting both
inhibitory and excitatory receptor systems. OMIM numbers for each gene are
detailed for more in-depth reference.
Genes: SCN1A: sodium channel a1 subunit; SCN1B: sodium channel b1 subunit;
SCN2A: sodium channel a2 subunit; CACNA1A: Voltage-dependant P/Q Type
Calcium channel a1; CACNB4: Voltage-dependant Calcium channel b4; CACNA1H:
Voltage-dependant T-type calcium channel a1H; CHRNA4: acetylcholine receptor
subunit,a4; CHRNB2: acetylcholineb2 receptor subunit;GABRA1: GABBAA receptor
a1 subunit; GABRG2: GABBAA receptor g2 subunit; GABRD: GABBAA receptor d
subunit CLCN2: chloride channel gene 2; KCNQ2/KCNQ3: potassium channel
subunits; LG11: leucine-rich, glioma inactivated 1 gene.
Syndromes: ADNFLE: autosomal dominant nocturnal frontal lobe epilepsy; BFNC:
benign familial neonatal convulsions; GEFS+: generalised epilepsy with febrile
seizures plus; SMEI: severe myoclonic epilepsy of infancy; CAE: childhood absence
epilepsy; FS: febrile seizures; BFNIS: benign familial neonatal-infantile seizures;
ADJME: autosomal dominant juvenile myoclonic epilepsy; IGE: idiopathic
generalised epilepsy; ADPEAF: autosomal dominant partial epilepsy with auditory
features; JME: juvenile myoclonic epilepsy; EGMA: epilepsy with grand mal upon
wakening.
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the pedigree members is well-deﬁned. These patterns in large
families are often AD with reduced penetrance but with some
recent examples of recessive and X-linked inheritance in
cryptogenic epilepsy yielding new genes in consanguineous
families.5,6 That said, the vast majority of familial epilepsy has
an undetermined inheritance pattern and often does not reach the
statistically demanding limits of parametric linkage experiments.
Therefore, informative families from genetics perceptive are
certainly rare, but remain powerful and relevant for indentifying
genes that are informative for the private family and become
immediate candidate genes for further analysis in families and
unrelated populations with the same phenotype. In addition, any
new gene spawns frantic activity amongst scientists who chase the
neurobiological mechanism underling the epilepsy – ranging from
specialised electrophysiology to animal model experts. More
importantly, great care must be taken with families who are
consented into research since the investigation of the ‘epilepsy
family’ can have both profound positive and negative outcomes as
revealed by Hammond et al. in this edition of Seizure.
3. An avalanche of channelopathies
The majority of genes detailed in Table 1 represent subunit
components of multi-meric receptor channels which mediate K+,Na+, Ca2+, and GABA voltage-gated/ligand-gated neurotransmis-
sion or ensure neuronal homeostasis/function. The majority of
these ion channel genes are generally segregated into mediating
excitatory or inhibitory neurotransmission and normally found in
rare families where dominant mutations segregate with the
epilepsy phenotype, although there can be heterogeneous intra-
family expression of the phenotype. In most cases, each gene
mutation has functional validation of pathogenicity and the lack of
a functional evidence-base should be viewed with suspicion and
the genotype not regarded as a mutation, but rather as a rare
variant, even if there is signiﬁcant segregation of a gene variant
with the phenotype in any given family.
Conﬁrmation of a pathogenicmutation usually involves either a
proof-of principle in vitro assay or patch-clamp electrophysiology,
often in association with convergent data from sophisticated
clinical testing, advance medical imaging and animal models of
epilepsy that may involve analogous genes. As a result the main
pathogenic mechanism to emerge which leads to over-excitation
and synchronous ﬁring of neural networks is mirrored in other
channelopathy disorders. These can be (i) dominant missense
mutations that will compromise the channel current dynamics or
affect the efﬁcacy of ligand-binding, (ii) rare dominant missense
mutations that lock the receptor into a permanently open state of
tonic activity, or (iii) dominant and recessive nonsense mutations
that can trigger haploisufﬁcency or nonsense-mediated degrada-
tion of stop codon and frameshift polypeptides, leading to a
reduction of cell surface expression of the receptor.7 All conspire to
either increase excitability of neural networks or withdraw the
inhibitory tone in neurons and inter-neurones, with seizure events
determined by which networks are affected in conjunction with
clinically relevant issues around seizure initiation sites and spread
of synchronous ﬁring.8,9
(a) Excitatory ion channel genes: These include the sodium,
nicotinic acetylcholine and calcium channel genes which are
involved in BFNIS, ADNFLE, GEFS+, SMEI, JME and CAE epilepsy
sub-types. These channels belong to large gene-clusters which
contribute to the pathogenesis of other neuronal/electrical
conduction disorders such as long QT syndrome, Brugada
syndrome, hemiplegic migraine and paroxysmal paralysis cases.10
In particular, mutations in SCN1A in SMEI represents the best
example, to date, of a genetic ﬁnding in familial epilepsy that has
translated into a population-based diagnostic test. From discovery
of 600 mutations in SCN1A, approximately 90% arise as de novo
events and around half of these results in protein truncation and
haploinsufﬁciency (one intact gene-copy is not sufﬁcient to rescue
the phenotype). Latest research conﬁrms that the timing of these
de novomutations can occur at any time between parental gamete
formation (germ-line) and late premorula stage of the embryo
(event in affected case).11 The discovery of LGI-1 mutations in
autosomal dominant lateral–temporal lobe epilepsy with auditory
features (ADPEAF) presents another example of the transfer from
families (and animal models) to sporadic population based cases
with same phenotype. This was hailed as the ﬁrst non-channelo-
pathy mutation in IGE, which in terms of gene family is correct.
However, functional characterisation of this cancer susceptibility
gene revealed that it was a coupled protein partner of K+ Channels
directly related to channel function12 and recently shown to impair
postnatal development of glutamatergic circuits.13
(b) Inhibitory ion channels genes: These include the potassi-
um (K+), and chloride channel (Cl) genes which are associated
with BFNC1 and 2, EA1, JME, CAE, GEFS+, and ADPEAF epilepsy
phenotypes. The principal role of K channels is stabilization of the
cell membrane potential by terminating, dampening and lowering
excitatory inputs into the cell. It is logical that removal of this
inﬂuence may trigger indiscreet synchronous neuronal-network
ﬁring in epilepsy, although mutations in KCNQ2 and KCNQ3 result
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developmentally restricted to within the ﬁrst months of infancy.
The principal role of Cl channels is to mediate fast-response
inhibition and include the GABAA and Glycine receptor systems.
Mutations in GABAA subunits (g2, a1, and d) are associated with
GEFS+, CAE and JME, although only in small proportion and with
disappointing effect on a population basis. Glycine receptor
mutations cause human hyperekplexia, a non-epileptic paroxys-
mal disorder, which can often cause anoxic seizures and brain
damage in neonates.14
4. Epilepsia syndromica
Syndromic epilepsy is a wider source of genetic discoveries in
disorders where epilepsy is co-morbid with other pathology but is
not necessarily the most morbid factor of the core presentation.
Examples include syndromes with learning difﬁculties (LD) and
cognitive decline, migraine, cortical malformation disorders and
mitochondrial/metabolic disorders. Some recent examples are
given below, but this is by no means a full compendium of genes
and disorders in this category.
(a) Learning difﬁculties and intellectual disabilities –
autosomal and X-linked: Epilepsy is one of the most common
secondary disabilities in people with cognitive impairment and
learning difﬁculties, the prevalence increasing with the severity of
the intellectual disability. About 50% of those with profound
learning disability and between 10% and 20% of those with mild
disability suffer from lifetime seizures. Epilepsy is thus an
important indicator of underlying cerebral dysfunction and the
aetiologies for syndromic and non-syndromic cognitive im-
pairment are varied and involve a wide spectrum of autosomal
and X-linked genetic determinants (over 300 genes – see 15,16).
This strongly suggests that cognitive impairment and LD can
emerge within a common pathway of many different types of
abnormal cellular processing with no one overriding or dominant
mechanism. Some of these mechanisms include defects in
neuronal signalling molecules, components of vesicular and
neuronal architecture/dynamics, transcription factors and enzy-
matic regulation. Undoubtedly, there are more genes to be
identiﬁed and all have the potential to unveil an epileptogenic
mechanism and become a target for further research in IGE.
(b) Neuronal migration disorders: The majority of patients
showing neuronal migration disorders in cortical structures suffer
from pharmaco-resistant epilepsy. The introduction of non-
invasive MRI imaging of the brain is responsible for the increased
phenotypic hierarchical classiﬁcation of cortical development
disorders as a cause of epilepsy in conjunction with cognitive
defects and developmental delay. In addition to the imaging
advances, the molecular delineation of the neuronal migration
disorders have revealed correlations with steps in cortical
development at stages which include migration of neurones and
proliferation of neural progenitors. Epilepsy is particularly
prevalent in classical lissencephaly where normal gyration of
the cortex is absent or reduced and there are four cortical layers
instead of the normal six layers. There are two major genes
associated with lissencephaly, namely LIS1 (platelet activating
factor acetohydrolase beta subunit) and X-linked DCX (double-
cortin) and more recently the tubulin genes (TUBA1A, TUBA2B).
These genes work together in the biochemical pathway which
regulates microtubule formation, stimulates microtubule poly-
merisation and neuronal motility.17
(c) Neuropsychiatric disorders: In the community, epilepsy is
associatedwith an increased prevalence ofmental health disorders
compared with the general population. Patients with epilepsy are
about two and a half times more likely to have schizophrenia and
almost three times more likely to have schizophrenia-likepsychosis than people without epilepsy. Epilepsy is also associated
with a higher prevalence of suicidal ideation and anxiety disorders.
All of these neuropsychiatric traits have very high rates of
heritability (or genetic loading) and are presently being intensely
investigated through the new genetic mapping techniques. The
epilepsy gene-hunting laboratories would be well advised to
mimic best-practice guidelines and the exhaustive efforts of the
neuropsychiatric genetics work and not attempt to re-invent the
wheel as the new genetics era emerges (International Schizophre-
nia Consortium).
5. The morning after the night before – waking up to complex
genetics
Let us be honest – the epilepsy community has been spoilt by
the gene-discovery in Mendelian families which unintentionally
delayed the hard truth – like other complex disorders, the
heritability of epilepsy on a population basis is logistically complex
and driven by polygenic susceptibility loci. Application of linkage
analysis to complex epilepsy has suggested various susceptibility
loci, but these ﬁndings have a very poor record of replication. This
approach has failed to uncover a ‘common epilepsy gene’,
validating the concern that complex epilepsy syndromes may be
too genetically heterogeneous for the proposed SNP-based disease
association approach to succeed. Non-replicable case–control
candidate gene (genome-wide or candidate gene/hypothesis-
driven) or transmission disequilibrium tracking with disease
association (SNP haplotypes) has failed to identify new genes
for complex epilepsy. Association studies have traditionally been
underpowered to detect any small effects of polygenes. Genetic
associations with epilepsy have a poor record of replication, either
because of underlying ascertainment bias, prior assumptions of the
degree of heterogeneity or sensitivity to the statistical pitfalls of
multiple testing.
However, it is now apparent that genome-wide searching for
genes of effect is becoming more successful in the background of
the genome project, the SNP HapMap resource, faster technology
platforms and high-speed supercomputing. In 2007, Cavalleri
et al.18 described the ﬁrst serious attempt to deliver a multi-
institutional, large-population study in epilepsy genetics. Despite
the lack of positive results this reﬂected on the issues which would
make future experiments worthwhile, quoting several factors such
as better standard of clinical phenotyping (and breaking down to
endo-phenotypes), collection of large standardised multi-centre
cohorts and access to genome centres and computing power.
Furthermore, large cohorts of IGE samples are being screened
through new genomic platforms such as Array-CGH panels where
the search for large genome-wide deletions, insertions and
duplications are underway. This has already been a successful
platform in syndromic epilepsy and in case studies with
intellectual disability, as well as many other disorders such as
autism/ADHD, schizophrenia, and cancer.19
6. Epilepsy genetics – the future
In the short term the next few years will see the publication of
studies which reﬂect the multicentre efforts in candidate gene
screening, SNP array genome-wide association studies, Array CGH,
as well as laboratory efforts to understand the biology of known
and emerging genes. Ticking away in the background will be more
gene-discovery in Mendelian families, recessive mapping of
consanguineous alleles, a plethora of syndromic epilepsy co-
morbid with other phenotypes, and animal models to aid our
neurobiological understanding of epileptogenesis. However, times
are changing and approaching rapidly on the horizon is a
revolution in genetics which will initiate a new approach and
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begins with excellent phenotyping and efforts are underway to
improve seizure diagnosis and deﬁne variation with phenotypes
and clinical presentation. For example the deep phenotyping of
CAE or JMEmay yield endo-phenotypic categorieswhichwill select
for great genetic homogeneity and easier interpretation of
downstream genetic analysis. This concept is widely adopted in
other complex disorders and the ‘Emperor’s new clothes’ will
become apparent in due course.
What is changing rapidly is the application of whole-genome
sequencing to medical genetics research. Although personalised
WGS is still prohibitively expensive, it is the affordability of exome
sequencing which is exciting, promising and daunting. Exciting
because exome sequencingwill sequence the entire coding regions
of the majority of genes in a given genome; promising because it
has the capacity to pull out the disorder-speciﬁc genotypes and
reveal genetic heterogeneity/proteome implication; and daunting
because the bioinformatic challenge is substantial even though it is
only 1–2% of the genome and it has the capacity to deﬁne other
disorders outside the focus of the study. Given the power of this
approach and the requirement for small numbers of cases, it is
likely that exome sequencing will have an increasing proﬁle in
epilepsy research in the next 5 years. The ﬁrst discoveries using
this platform are now published20,21 andmost experts agree that it
is step-change in medical genetics.
Where will be sixty years from now? If we consider that 60
years ago that DNAwas a ﬂedgling science andmedical genetics an
embryonic clinical priority, then we can expect several evolutions
and a landscape which may be too difﬁcult to predict. The pace of
change in methodologies, technology capability, bioinformatics
and super-computing is already evident and so the ﬁrst safe
prediction is that personalised genomes will be as accessible as
other pathology tests and will also compliment pathology indices
by explaining the biomarker results. The second is that the Brave
New World in genetics will have signiﬁcant challenges during
development because of the ethical dilemmas of multiple
susceptibilities and health service loading on counselling services.
The third is that most, if not all, of the epilepsy predisposition
geneswill have been identiﬁed and characterised on a cellular and
physiological basis and be a standard interpretation at the clinical
level. The fourth, andmost important, is that interventionswill be
available, not necessarily drugs, rather more advances in
autologous cell therapy, neural network manipulation and
nano-technology. If we are still disappointingly reliant on
pharmacology in 2070, then certainly the drugs will be more
speciﬁc and personalised, with responsiveness and side-effect
proﬁles revealed before administration. Lastly, it is to be hoped
that health service delivery to epilepsy patients will be deter-
mined by care plans that are holistic, integrated, multi-disciplin-
ary and not mired in politics or ﬁnancial austerity, or limited by a
lack of knowledge.Conﬂict of interest statement
None declared.
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